| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.067 | 0.05 |
| mRNA | Bleomycin | GDSC1000 | pan-cancer | AAC | -0.073 | 0.05 |
| mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | 0.072 | 0.05 |
| mRNA | SCH-529074 | CTRPv2 | pan-cancer | AAC | 0.076 | 0.05 |
| mRNA | KIN001-102 | GDSC1000 | pan-cancer | AAC | 0.059 | 0.05 |
| mRNA | ML006 | CTRPv2 | pan-cancer | AAC | 0.074 | 0.05 |
| mRNA | BRD-K66532283 | CTRPv2 | pan-cancer | AAC | 0.066 | 0.05 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.12 | 0.05 |
| mRNA | ZSTK474 | CTRPv2 | pan-cancer | AAC | 0.072 | 0.06 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.066 | 0.06 |